Cartesian Therapeutics Appoints CAR-T Pioneer Adrian Bot to Board of Directors
Key Insights
Cartesian Therapeutics has appointed Adrian Bot (search), M.D., Ph.D., a veteran biopharma executive with three decades of R&D experience, to its Board of Directors.
Dr. Bot brings extensive expertise in CAR-T cell therapies, having contributed to first-in-class cancer (search) treatments at Kite Pharma (search) and founding Capstan Therapeutics (search).
The appointment comes as Cartesian advances its lead asset Descartes-08, a CAR-T therapy in Phase 3 trials for generalized myasthenia gravis (search).
Cartesian Therapeutics, Inc. (NASDAQ: RNAC), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases (search), announced the appointment of Adrian Bot (search), M.D., Ph.D., to its Board of Directors. Dr. Bot brings three decades of research and development experience focused on immune, cell, gene therapy and nanomedicines to the Frederick, Maryland-based company.
Strategic Leadership Addition
Dr. Bot will serve as a member of the Science and Technology Committee of the Board, bringing expertise from his role as founding Chief Scientific Officer and Executive Vice President of R&D at Capstan Therapeutics (search), which developed next-generation RNA-based precision medicines. His appointment comes at a critical juncture as Cartesian advances its pipeline and explores expansion beyond ex-vivo cell therapy.
"Dr. Bot brings a unique perspective shaped by pioneering work in first-in-class CAR T cell therapies, including the recent historic acquisition of Capstan's novel in-vivo CAR T technology by Abbvie (search), as well as the development of next generation RNA-based precision medicines," said Carsten Brunn, Ph.D., President and Chief Executive Officer of Cartesian. "His dynamic expertise will be particularly valuable while we continue to advance our current pipeline and explore potential opportunities beyond ex-vivo cell therapy."
Extensive CAR-T Experience
Dr. Bot's career includes significant leadership roles at Kite Pharma (search) and Kite, a Gilead Company, where he served as Chief Scientific Officer, Global Head of Translational Medicine and Head of Discovery Research. At Kite, he contributed to the development of first-in-class CAR T cell therapy products for cancer (search). He also held senior R&D leadership positions at MannKind (search) and Alliance Pharma (search).
"Cartesian is at the forefront of expanding the reach of powerful cell therapies to autoimmunity, advancing a well-differentiated technology with exciting clinical activity and a favorable safety profile," said Dr. Bot. "I look forward to bringing a fresh perspective, as well as industry expertise in the immune engineering space, and working alongside the talented leadership team and Board as the Company continues to execute on its important mission."
Academic and Research Background
Dr. Bot has co-authored more than 200 peer-reviewed manuscripts, abstracts, book chapters, and monographs throughout his career. He received his M.D. from the University of Medicine and Pharmacy in Timisoara, Romania, and a Ph.D. in Biomedical Sciences at Mount Sinai School of Medicine.
Current Pipeline Development
Cartesian's lead asset, Descartes-08, is currently in Phase 3 clinical development for patients with generalized myasthenia gravis (search) through the ongoing AURORA trial. The company also plans to initiate a Phase 2 trial of Descartes-08 in myositis (search), expanding the therapeutic application of their CAR-T platform to additional autoimmune conditions.
The appointment positions Cartesian to leverage Dr. Bot's experience in immune engineering and cell therapy development as the company continues advancing its autoimmune-focused pipeline and evaluating new therapeutic opportunities in the evolving cell therapy landscape.